Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

VICTORIA, BC, Nov. 14, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting a poster at the American College of Rheumatology (the "ACR") Convergence 2024 Annual Meeting, being held in Washington, D.C. from November 14-19, 2024.

Read more at prnewswire.com